Experimental and investigational · Research guide

LOY-002: how close is a longevity drug for senior dogs?

What the STAY study and FDA development milestones tell us, without confusing progress with proven lifespan extension.

The takeaway

Nara’s take.

LOY-002 is a serious attempt to turn canine ageing biology into a tested medicine. The key distinction is between a drug moving toward authorization and one already shown to help senior dogs live longer in a completed pivotal trial.

How it may work

What Loyal is trying to target

The sponsor describes LOY-002 as a daily oral drug aimed at age-associated metabolic dysfunction in senior dogs. That is a different programme from LOY-001's large-dog growth-signalling rationale.

Canine research linking metabolic measures with frailty and quality of life helps explain the scientific interest. It is observational evidence about ageing biology, not proof that LOY-002 changes those outcomes or that an owner should try to manipulate insulin independently.

Sources: [1], [2]

What the research shows

The current milestones are real, but narrower than 'approved'

At the 24 September 2026 check, Loyal reported acceptance of its reasonable-expectation-of-effectiveness and target-animal-safety sections, while the manufacturing section remained in progress. Those are sponsor-reported steps toward conditional approval, not a completed approval announcement.

FDA's explanation of conditional approval makes the distinction important: the effectiveness threshold for that pathway differs from the substantial evidence required for full approval. Meeting a preliminary threshold should not be rewritten as demonstrated lifespan extension in the general pet population.

Sources: [3], [4]

What the research shows

What STAY is meant to answer

STAY is the sponsor's randomized, blinded, placebo-controlled effectiveness study in senior dogs. Its purpose is to determine whether the intervention delivers the hoped-for benefit, rather than simply showing that a relevant biomarker can move.

Recruitment, enrolment and ongoing follow-up are not positive efficacy results. Nara's editorial check did not verify a completed pivotal survival result. The useful future evidence will include how dogs felt and functioned, adverse outcomes, and the magnitude of benefit—not just whether a statistical threshold was crossed.

Sources: [3], [5]

Nara's practical guidance

What this means for your dog

Treat launch dates and eventual cost as uncertain until the official authorization, product information and access arrangements are available. Trial eligibility or a sponsor's intended population does not automatically mean the drug would be appropriate for every senior dog.

Nara would bring future decisions to the dog's veterinary team with a clear account of existing disease, medicines and goals. A promising medicine can complement good care if its benefit is demonstrated; waiting for it should not delay investigation of pain, weight loss, cognitive change or other problems that can be addressed now.

Evidence informing this guidance: [1], [3], [4]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2026 · Dog · Sponsor development disclosure; not independent efficacy evidence
Loyal: products in development
Loyal Animal Health. Loyal.
Official product pipeline checked 2026-09-24
Distinguishes LOY-001, LOY-002 and LOY-003, formulations and development status.
[2] 2025 · Dog · Cross-sectional canine observational study
Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogs
McKenzie B, Peloquin M, Graves JL, Chen F, Tovar A, Carttar TA, Tucker K, Vo K, Nelson M, Super KM, Austriaco J, Weber SY, Naka A, McCandless EE, Greenwood K, Juarez-Salinas D, Halioua-Haubold CL, et al.. Scientific Reports.
10.1038/s41598-025-89923-z
Provides canine metabolic-aging associations relevant to biological plausibility but does not test either LOY drug or establish causal therapeutic benefit.
[3] 2026 · Dog · Sponsor status disclosure; not a completed trial result
Loyal: LOY-002 development and technical-section status
Loyal Animal Health. Loyal.
Official homepage status checked 2026-09-24
Sponsor-reported RXE and target-animal-safety milestones and manufacturing work in progress.
[4] 2026 · Veterinary regulatory framework · Official regulatory explanation
Conditional Approval Explained: A Resource for Veterinarians
U.S. Food and Drug Administration, Center for Veterinary Medicine. FDA.
Official guidance checked 2026-09-24
Distinguishes technical-section milestones, conditional approval and full approval.
[5] 2026 · Dog · Ongoing randomized double-blind placebo-controlled clinical trial description
Clinical trials — STAY study
Loyal Animal Health. Loyal Animal Health.
STAY clinical-development registry/information page
Documents approximately 1,300 enrolled dogs and identifies STAY as the pivotal effectiveness study for LOY-002; provides no efficacy outcome.

Keep reading

Connected questions.

LOY-001

An investigational large-breed longevity candidate targeting IGF-1 signalling.

Rapamycin

The most scientifically important experimental canine longevity intervention, and still a medication-level decision.

Preventive care

Screening cadence, early detection, and baseline diagnostics before decline is visible.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Clinical-trial context only

Hypothesis-generatingCanine safety or pharmacokineticsVery low confidence

The claim we’re evaluating

LOY-002 has substantial ongoing canine clinical-development and target-animal safety evidence, but no publicly reported pivotal result currently demonstrates that LOY-002 extends canine healthspan or lifespan.

Nara’s interpretation

LOY-002 is one of the most advanced canine longevity drug programs, but advanced development is not the same thing as demonstrated efficacy. FDA has accepted both its Reasonable Expectation of Effectiveness and Target Animal Safety sections, while the large randomized STAY study remains the study intended to establish whether treatment actually affects survival and health. Nara should therefore describe LOY-002 as a serious clinical experiment rather than a proven longevity intervention.

How we reached this view

What the evidence shows

Loyal reports that FDA accepted LOY-002's Reasonable Expectation of Effectiveness section in 2025 and its Target Animal Safety section in late 2025, announced January 2026. The disclosed safety package included a standard target-animal safety study at multiples of intended exposure and field-safety experience in more than 400 dogs, including dogs followed for up to one year, with no clinically significant adverse events reported at the tested multiples. Detailed underlying safety data remain incompletely public. STAY is a fully enrolled double-blinded placebo-controlled study involving roughly 1,300 dogs and is the pivotal effectiveness study for LOY-002. Enrollment and regulatory progress are not efficacy outcomes.

Important limitations

The active pharmaceutical ingredient and exact mechanism remain undisclosed publicly, limiting independent pharmacologic evaluation.
The RXE standard is not the substantial-evidence standard for full approval.
The accepted Target Animal Safety section provides meaningful safety evidence but does not establish efficacy.
STAY remains blinded/in development; enrollment provides no information about whether efficacy will be positive, null, or harmful.

What would change Nara’s view

What would strengthen our view

Prespecified STAY results demonstrating statistically and clinically meaningful improvement in survival.
Concurrent preservation or improvement of validated health, function, or quality-of-life endpoints.
Publication of complete target-animal and field-safety datasets.

What could weaken our view

A neutral or negative STAY primary survival result.
Longer survival accompanied by worse function or quality of life.
Emergence of clinically important adverse effects with longer exposure or larger populations.

What could change our position

A convincing positive STAY healthspan/survival result with acceptable safety could justify veterinary_or_clinical_context.
Subsequent substantial evidence supporting actual lifespan extension would warrant a major upgrade in Nara's longevity assessment.
A negative pivotal trial would move the lifespan-extension claim toward not_currently_supported.

Safety and clinical context

FDA acceptance of the Target Animal Safety section is materially stronger safety evidence than trial registration alone.
That acceptance does not answer whether benefits outweigh risks because pivotal efficacy remains unresolved.
Regulatory availability would still not be equivalent to full demonstration of effectiveness.

Evidence record

Nara position: Clinical-trial context only
Evidence maturity: Hypothesis-generating
Most direct relevant evidence: Canine safety or pharmacokinetics
Overall confidence: Very low confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

Conditional Approval Explained: A Resource for Veterinarians

U.S. Food and Drug Administration · 2026 · Veterinary regulatory framework

Authoritative regulatory guidance

Establishes that reasonable expectation of effectiveness is a lower effectiveness standard than substantial evidence required for full approval.

FDA CVM conditional-approval guidance, updated 2026-05-11

One step closer to a dog longevity drug: What LOY-002's safety milestone means to a practicing vet

Loyal Animal Health · 2026 · Dog

Sponsor regulatory and safety disclosure

Reports FDA acceptance of the Target Animal Safety section and summarizes safety exposure in more than 400 dogs.

LOY-002 TAS announcement, 2026-01-13

Clinical trials — STAY study

Loyal Animal Health · 2026 · Dog

Ongoing randomized double-blind placebo-controlled clinical trial description

Documents approximately 1,300 enrolled dogs and identifies STAY as the pivotal effectiveness study for LOY-002; provides no efficacy outcome.

STAY clinical-development registry/information page

Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogs

Scientific Reports · 2025 · Dog

Cross-sectional canine observational study

Provides canine metabolic-aging associations relevant to biological plausibility but does not test either LOY drug or establish causal therapeutic benefit.

10.1038/s41598-025-89923-z

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…